T1	Age 10 21	53-year-old
T2	Sex 22 26	male
T3	Sign_symptom 96 104	bleeding
E1	Sign_symptom:T3 
T4	Duration 109 114	1 day
E2	Duration:T4 
T5	Clinical_event 39 43	went
E3	Clinical_event:T5 
T6	Nonbiological_location 51 59	hospital
R1	MODIFY Arg1:T6 Arg2:E3	
T7	Severity 84 91	massive
T8	Biological_structure 92 95	gum
R2	MODIFY Arg1:T8 Arg2:E1	
R3	MODIFY Arg1:T7 Arg2:E1	
T9	History 145 164	chronic hepatitis C
T10	Detailed_description 145 152	chronic
T11	Disease_disorder 153 164	hepatitis C
E4	Disease_disorder:T11 
T12	Medication 166 178	PEG-IFN-α-2a
E5	Medication:T12 
T13	Dosage 180 186	180 μg
R4	MODIFY Arg1:T13 Arg2:E5	
T14	Medication 193 202	ribavirin
E6	Medication:T14 
T15	Dosage 204 215	1200 mg/day
R5	MODIFY Arg1:T15 Arg2:E6	
T16	Duration 248 268	since March 17, 2014
E7	Duration:T16 
T17	History 273 305	denied any autoimmune conditions
T18	Diagnostic_procedure 337 353	virological data
E8	Diagnostic_procedure:T18 
T19	Diagnostic_procedure 368 378	virus load
E9	Diagnostic_procedure:T19 
R6	SUB_PROCEDURE Arg1:E9 Arg2:E8	
T21	Diagnostic_procedure 380 387	HCV RNA
E10	Diagnostic_procedure:T21 
R8	SUB_PROCEDURE Arg1:E10 Arg2:E9	
T22	Lab_value 388 403	2.1 × 106 IU/mL
R9	MODIFY Arg1:T22 Arg2:E10	
T23	Diagnostic_procedure 410 418	genotype
E11	Diagnostic_procedure:T23 
R10	SUB_PROCEDURE Arg1:E11 Arg2:E8	
#1	AnnotatorNotes E8	Specifically, of Hepatitis C
T25	Diagnostic_procedure 487 494	HCV RNA
E12	Diagnostic_procedure:T25 
T26	Lab_value 496 512	2.12 × 106 IU/mL
R12	MODIFY Arg1:T26 Arg2:E12	
T27	Clinical_event 2874 2884	discharged
E13	Clinical_event:T27 
T20	Lab_value 419 421	1b
E14	Lab_value:T20 
R7	MODIFY Arg1:E14 Arg2:E11	
T24	Lab_value 363 367	high
E15	Lab_value:T24 
R11	BEFORE Arg1:E15 Arg2:E9	
T28	Sign_symptom 429 449	virological response
E16	Sign_symptom:T28 
A1	POLARITY E16 NEG
T29	Detailed_description 423 428	Rapid
R13	MODIFY Arg1:T29 Arg2:E16	
T30	Date 474 485	fourth week
E17	Date:T30 
T31	Sign_symptom 529 549	virological response
E18	Sign_symptom:T31 
T32	Detailed_description 523 528	early
T33	Detailed_description 515 522	Partial
R14	MODIFY Arg1:T32 Arg2:E18	
R15	MODIFY Arg1:T33 Arg2:E18	
T34	Diagnostic_procedure 551 558	HCV RNA
E19	Diagnostic_procedure:T34 
T35	Diagnostic_procedure 616 623	HCV RNA
E20	Diagnostic_procedure:T35 
T36	Lab_value 560 569	103 IU/mL
E21	Lab_value:T36 
T37	Lab_value 625 634	<15 IU/mL
E22	Lab_value:T37 
R16	MODIFY Arg1:E22 Arg2:E20	
R17	MODIFY Arg1:E21 Arg2:E19	
T38	Date 573 580	week 12
E23	Date:T38 
T39	Date 638 645	Week 24
E24	Date:T39 
T40	Sign_symptom 668 675	fatigue
E25	Sign_symptom:T40 
T41	Sign_symptom 677 683	anemia
E26	Sign_symptom:T41 
T42	Sign_symptom 689 708	depression syndrome
E27	Sign_symptom:T42 
A2	TREND E27 INC
A3	TREND E26 INC
A4	TREND E25 INC
T43	Date 728 737	30th week
E28	Date:T43 
T44	Date 782 789	Week 36
E29	Date:T44 
T45	Medication 769 778	treatment
E30	Medication:T45 
A5	POLARITY E30 NEG
T46	Date 813 829	end-of-treatment
E31	Date:T46 
T47	Diagnostic_procedure 795 805	viral load
E32	Diagnostic_procedure:T47 
T48	Lab_value 840 852	undetectable
E33	Lab_value:T48 
R18	MODIFY Arg1:E33 Arg2:E32	
T49	Date 2845 2856	December 15
E34	Date:T49 
T50	Sign_symptom 2892 2908	stable condition
E35	Sign_symptom:T50 
T51	Diagnostic_procedure 2914 2929	platelet counts
E36	Diagnostic_procedure:T51 
T52	Lab_value 2930 2939	elevating
E37	Lab_value:T52 
R19	MODIFY Arg1:E37 Arg2:E36	
T53	Lab_value 2943 2961	117 × 103 cells/μL
E38	Lab_value:T53 
R20	MODIFY Arg1:E38 Arg2:E36	
T54	Diagnostic_procedure 2984 2999	laboratory data
E39	Diagnostic_procedure:T54 
T55	Sign_symptom 3034 3052	virologic response
E40	Sign_symptom:T55 
T56	Detailed_description 3024 3033	sustained
R21	MODIFY Arg1:T56 Arg2:E40	
T57	Date 3000 3014	after 5 months
E41	Date:T57 
T58	Diagnostic_procedure 3054 3068	platelet count
E42	Diagnostic_procedure:T58 
T59	Lab_value 3069 3093	above 150 × 103 cells/μL
E43	Lab_value:T59 
R22	MODIFY Arg1:E43 Arg2:E42	
T60	Diagnostic_procedure 3109 3129	anti-cardiolipin IgG
E44	Diagnostic_procedure:T60 
T61	Lab_value 3099 3108	decreased
E45	Lab_value:T61 
R23	MODIFY Arg1:E45 Arg2:E44	
T62	Lab_value 3131 3138	30.5GPL
E46	Lab_value:T62 
R24	MODIFY Arg1:E46 Arg2:E44	
T63	Diagnostic_procedure 3144 3165	anti-phospholipid IgG
E47	Diagnostic_procedure:T63 
T64	Lab_value 3167 3174	73.21 U
E48	Lab_value:T64 
R25	BEFORE Arg1:E48 Arg2:E47	
R26	MODIFY Arg1:E45 Arg2:E47	
T65	Diagnostic_procedure 858 872	platelet count
E49	Diagnostic_procedure:T65 
T66	Date 876 879	EOT
E50	Date:T66 
T67	Date 831 834	EOT
E51	Date:T67 
R27	IDENTICAL Arg1:E51 Arg2:E31	
T68	Lab_value 884 901	92 × 103 cells/μL
E52	Lab_value:T68 
R28	MODIFY Arg1:E52 Arg2:E49	
T69	Lab_value 906 914	elevated
E53	Lab_value:T69 
T70	Lab_value 918 936	159 × 103 cells/μL
E54	Lab_value:T70 
T71	Date 937 949	1 week later
E55	Date:T71 
R29	MODIFY Arg1:E53 Arg2:E49	
R30	MODIFY Arg1:E54 Arg2:E49	
T72	Date 951 974	Two weeks following EOT
E56	Date:T72 
T73	Sign_symptom 1010 1018	bleeding
E57	Sign_symptom:T73 
T74	Biological_structure 1006 1009	gum
R31	MODIFY Arg1:T74 Arg2:E57	
T75	Severity 998 1005	massive
R32	MODIFY Arg1:T75 Arg2:E57	
T76	Sign_symptom 1065 1074	petechiae
E58	Sign_symptom:T76 
T77	Quantitative_concept 1056 1064	multiple
R33	MODIFY Arg1:T77 Arg2:E58	
T78	Biological_structure 1082 1093	extremities
R34	MODIFY Arg1:T78 Arg2:E58	
T79	Diagnostic_procedure 1024 1044	physical examination
E59	Diagnostic_procedure:T79 
T80	Sign_symptom 1129 1139	hemorrhage
E60	Sign_symptom:T80 
A6	POLARITY E60 NEG
T81	Biological_structure 1115 1128	intracerebral
R35	MODIFY Arg1:T81 Arg2:E60	
T82	Biological_structure 1141 1157	gastrointestinal
T83	Sign_symptom 1158 1166	bleeding
E61	Sign_symptom:T83 
A7	POLARITY E61 NEG
R36	MODIFY Arg1:T82 Arg2:E61	
T84	Diagnostic_procedure 1208 1222	platelet count
E62	Diagnostic_procedure:T84 
T85	Detailed_description 1200 1207	initial
R37	MODIFY Arg1:T85 Arg2:E62	
T86	Lab_value 1227 1242	4 × 103cells/μL
E63	Lab_value:T86 
R38	MODIFY Arg1:E63 Arg2:E62	
T87	Diagnostic_procedure 1244 1263	Coagulation profile
E64	Diagnostic_procedure:T87 
T88	Lab_value 1271 1277	normal
E65	Lab_value:T88 
T89	Diagnostic_procedure 1278 1294	prothrombin time
E66	Diagnostic_procedure:T89 
R39	MODIFY Arg1:E65 Arg2:E66	
R40	SUB_PROCEDURE Arg1:E66 Arg2:E64	
T90	Diagnostic_procedure 1296 1333	activated partial thromboplastin time
E67	Diagnostic_procedure:T90 
T91	Diagnostic_procedure 1335 1345	fibrinogen
E68	Diagnostic_procedure:T91 
T92	Diagnostic_procedure 1347 1354	d-dimer
E69	Diagnostic_procedure:T92 
T93	Diagnostic_procedure 1360 1386	fibrin degradation product
E70	Diagnostic_procedure:T93 
R41	MODIFY Arg1:E65 Arg2:E67	
R42	MODIFY Arg1:E65 Arg2:E68	
R43	MODIFY Arg1:E65 Arg2:E69	
R44	MODIFY Arg1:E65 Arg2:E70	
R45	SUB_PROCEDURE Arg1:E67 Arg2:E64	
R46	SUB_PROCEDURE Arg1:E68 Arg2:E64	
R47	SUB_PROCEDURE Arg1:E69 Arg2:E64	
R48	SUB_PROCEDURE Arg1:E70 Arg2:E64	
T94	Diagnostic_procedure 1388 1410	Peripheral blood smear
E71	Diagnostic_procedure:T94 
T95	Sign_symptom 1426 1452	fragmented red blood cells
E72	Sign_symptom:T95 
A8	POLARITY E72 NEG
T96	Sign_symptom 1454 1466	helmet cells
E73	Sign_symptom:T96 
A9	POLARITY E73 NEG
T97	Sign_symptom 1471 1500	abnormal platelet aggregation
E74	Sign_symptom:T97 
A10	POLARITY E74 NEG
T98	Disease_disorder 1525 1551	connective tissue diseases
E75	Disease_disorder:T98 
A11	POLARITY E75 NEG
T99	Disease_disorder 1560 1588	systemic lupus erythematosus
E76	Disease_disorder:T99 
A12	POLARITY E76 NEG
T100	Disease_disorder 1592 1608	cryoglobulinemia
E77	Disease_disorder:T100 
A13	POLARITY E77 NEG
T101	Diagnostic_procedure 1639 1660	anti-nuclear antibody
E78	Diagnostic_procedure:T101 
T102	Diagnostic_procedure 1665 1677	cryoglobulin
E79	Diagnostic_procedure:T102 
T103	Lab_value 1630 1638	negative
E80	Lab_value:T103 
R49	MODIFY Arg1:E80 Arg2:E78	
R50	MODIFY Arg1:E80 Arg2:E79	
T104	Diagnostic_procedure 1698 1718	anti-cardiolipin IgG
E81	Diagnostic_procedure:T104 
T105	Lab_value 1689 1697	positive
E82	Lab_value:T105 
R51	MODIFY Arg1:E82 Arg2:E81	
T106	Lab_value 1720 1727	116 GPL
E83	Lab_value:T106 
R52	MODIFY Arg1:E83 Arg2:E81	
T107	Diagnostic_procedure 1755 1776	anti-phospholipid IgG
E84	Diagnostic_procedure:T107 
T108	Lab_value 1778 1783	165 U
E85	Lab_value:T108 
R53	MODIFY Arg1:E85 Arg2:E84	
T109	Disease_disorder 1806 1832	Anti-phospholipid syndrome
E86	Disease_disorder:T109 
A14	POLARITY E86 NEG
T110	History 1853 1886	no previous thromboembolic events
T111	Diagnostic_procedure 1906 1922	Sapporo criteria
E87	Diagnostic_procedure:T111 
T112	Detailed_description 1901 1905	2006
R54	MODIFY Arg1:T112 Arg2:E87	
T113	Diagnostic_procedure 1938 1944	biopsy
E88	Diagnostic_procedure:T113 
T114	Biological_structure 1926 1937	Bone marrow
R55	MODIFY Arg1:T114 Arg2:E88	
T115	Sign_symptom 1980 1992	hypocellular
E89	Sign_symptom:T115 
T116	Diagnostic_procedure 2010 2031	cellular distribution
E90	Diagnostic_procedure:T116 
T117	Biological_structure 1993 1999	marrow
R56	MODIFY Arg1:T117 Arg2:E89	
R57	MODIFY Arg1:T117 Arg2:E90	
T118	Lab_value 2005 2009	even
E91	Lab_value:T118 
R58	MODIFY Arg1:E91 Arg2:E90	
T119	Disease_disorder 2056 2074	lymphoid neoplasia
E92	Disease_disorder:T119 
A15	POLARITY E92 NEG
T120	Medication 2510 2522	Azathioprine
E93	Medication:T120 
T121	Medication 2578 2596	Hydroxychloroquine
E94	Medication:T121 
T122	Dosage 2524 2530	100 mg
T123	Dosage 2538 2548	once daily
T124	Administration 2532 2536	oral
R59	MODIFY Arg1:T122 Arg2:E93	
R60	MODIFY Arg1:T123 Arg2:E93	
R61	MODIFY Arg1:T124 Arg2:E93	
T125	Dosage 2598 2604	400 mg
T126	Administration 2606 2610	oral
T127	Dosage 2612 2622	once daily
R62	MODIFY Arg1:T127 Arg2:E94	
R63	MODIFY Arg1:T125 Arg2:E94	
R64	MODIFY Arg1:T126 Arg2:E94	
T128	Diagnostic_procedure 2660 2688	anti-phospholipid antibodies
E95	Diagnostic_procedure:T128 
T129	Lab_value 2651 2659	positive
E96	Lab_value:T129 
R65	MODIFY Arg1:E96 Arg2:E95	
T130	Diagnostic_procedure 2690 2704	Platelet count
E97	Diagnostic_procedure:T130 
T131	Lab_value 2715 2724	increased
E98	Lab_value:T131 
R66	MODIFY Arg1:E98 Arg2:E97	
T132	Lab_value 2728 2745	93 × 103 cells/μL
E99	Lab_value:T132 
R67	MODIFY Arg1:E99 Arg2:E97	
T133	Date 2746 2769	17 days after admission
E100	Date:T133 
T134	Medication 2774 2792	methylprednisolone
E101	Medication:T134 
T135	Administration 2808 2812	oral
R68	MODIFY Arg1:T135 Arg2:E101	
T136	Dosage 2829 2840	tapered off
R69	MODIFY Arg1:T136 Arg2:E101	
T137	Date 2560 2576	since December 3
E102	Date:T137 
T138	Sign_symptom 2497 2508	improvement
E103	Sign_symptom:T138 
A16	POLARITY E103 NEG
T139	Medication 2354 2372	methylprednisolone
E104	Medication:T139 
T140	Administration 2342 2353	intravenous
T141	Dosage 2382 2402	40 mg, 3 times daily
R70	MODIFY Arg1:T141 Arg2:E104	
R71	MODIFY Arg1:T140 Arg2:E104	
T142	Date 2407 2418	November 27
E105	Date:T142 
T143	Therapeutic_procedure 2433 2464	platelet transfusion treatments
E106	Therapeutic_procedure:T143 
T144	Disease_disorder 2289 2320	immune thrombocytopenic purpura
E107	Disease_disorder:T144 
T145	Therapeutic_procedure 2142 2159	Blood transfusion
E108	Therapeutic_procedure:T145 
T146	Diagnostic_procedure 2196 2204	response
E109	Diagnostic_procedure:T146 
T147	Lab_value 2191 2195	poor
E110	Lab_value:T147 
R72	MODIFY Arg1:E110 Arg2:E109	
T148	Diagnostic_procedure 2227 2241	platelet count
E111	Diagnostic_procedure:T148 
T149	Lab_value 2210 2223	rapid decline
E112	Lab_value:T149 
R73	MODIFY Arg1:E112 Arg2:E111	
T150	Date 2249 2257	next day
E113	Date:T150 
T151	Medication 2090 2125	drugs that may cause platelet lysis
E114	Medication:T151 
A17	POLARITY E114 NEG
R74	AFTER Arg1:E3 Arg2:E1	
*	OVERLAP E1 E2
R75	AFTER Arg1:E2 Arg2:E4	
*	OVERLAP E4 E5 E6 E7
R76	BEFORE Arg1:E7 Arg2:E8	
R77	BEFORE Arg1:E8 Arg2:E16	
*	OVERLAP E16 E17 E12
R78	BEFORE Arg1:E12 Arg2:E18	
*	OVERLAP E18 E19 E23
R79	BEFORE Arg1:E23 Arg2:E20	
*	OVERLAP E20 E24
R80	BEFORE Arg1:E24 Arg2:E25	
*	OVERLAP E25 E26 E27 E28
R81	BEFORE Arg1:E28 Arg2:E30	
*	OVERLAP E30 E29
R82	BEFORE Arg1:E29 Arg2:E32	
*	OVERLAP E32 E31 E49 E50
R83	BEFORE Arg1:E50 Arg2:E55	
R84	MODIFY Arg1:E55 Arg2:E53	
R85	MODIFY Arg1:E55 Arg2:E54	
R86	BEFORE Arg1:E55 Arg2:E56	
*	OVERLAP E56 E57
R87	BEFORE Arg1:E57 Arg2:E59	
*	OVERLAP E59 E58 E60 E61 E62 E64 E71 E72 E73 E74 E75 E76 E77 E78 E79 E81 E84 E86 E87 E88 E89 E90 E92 E114 E108
R88	BEFORE Arg1:E108 Arg2:E109	
*	OVERLAP E109 E111 E113 E115
T152	Therapeutic_procedure 2261 2272	transfusion
E115	Therapeutic_procedure:T152 
R89	BEFORE Arg1:E115 Arg2:E107	
R90	BEFORE Arg1:E107 Arg2:E104	
*	OVERLAP E104 E105 E106
R91	BEFORE Arg1:E106 Arg2:E103	
R92	BEFORE Arg1:E103 Arg2:E93	
*	OVERLAP E93 E102 E94 E95
R93	BEFORE Arg1:E95 Arg2:E97	
*	OVERLAP E97 E100 E101
R94	BEFORE Arg1:E101 Arg2:E34	
*	OVERLAP E34 E13 E35 E36
R95	BEFORE Arg1:E36 Arg2:E39	
*	OVERLAP E39 E41 E40 E42 E44 E47
